Immunome Inc
IMNM13.920USD
-0.370-2.59%
Close 10/10, 16:00（ET）Quotes delayed by 15 min
1.21BMarket Cap
LossP/E TTM
More Details of Immunome Inc Company
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.
Immunome Inc Info
Ticker SymbolIMNM
Company nameImmunome Inc
IPO dateOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Number of employees118
Security typeOrdinary Share
Fiscal year-endOct 02
Address18702 N. Creek Parkway
CityBOTHELL
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code98011
Phone16103213700
Websitehttps://immunome.com/
Ticker SymbolIMNM
IPO dateOct 02, 2020
CEODr. Clay B. Siegall, Ph.D.
Company Executives of Immunome Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
40.73K
+117.46%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Ms. Sandra G. Stoneman
Ms. Sandra G. Stoneman
Chief Legal Officer, General Counsel, Corporate Secretary
Chief Legal Officer, General Counsel, Corporate Secretary
--
--
Dr. Phil Tsai
Dr. Phil Tsai
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Bob Lechleider, M.D.
Dr. Bob Lechleider, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kinney Horn
Mr. Kinney Horn
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Clay B. Siegall, Ph.D.
Dr. Clay B. Siegall, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
806.74K
+20.47%
Mr. Philip R. Wagenheim
Mr. Philip R. Wagenheim
Director
Director
406.15K
+3.44%
Mr. Isaac Barchas, J.D.
Mr. Isaac Barchas, J.D.
Lead Independent Director
Lead Independent Director
92.21K
-24.22%
Mr. Max Rosett
Mr. Max Rosett
Chief Financial Officer
Chief Financial Officer
47.48K
+139.10%
Dr. Jack Higgins, Ph.D.
Dr. Jack Higgins, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
40.73K
+117.46%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
36.41K
+15.92%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
4.01M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
T. Rowe Price Investment Management, Inc.
9.51%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Other
58.48%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
15.00%
T. Rowe Price Investment Management, Inc.
9.51%
BlackRock Institutional Trust Company, N.A.
5.94%
Redmile Group, LLC
5.60%
Enavate Sciences GP, LLC
5.48%
Other
58.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
43.36%
Investment Advisor/Hedge Fund
24.47%
Hedge Fund
12.05%
Corporation
8.25%
Research Firm
5.75%
Individual Investor
1.72%
Venture Capital
0.89%
Bank and Trust
0.31%
Pension Fund
0.21%
Other
2.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
325
82.71M
95.02%
-1.15M
2025Q2
326
85.20M
99.48%
+13.79M
2025Q1
320
89.38M
113.71%
+17.13M
2024Q4
278
64.18M
84.45%
+3.64M
2024Q3
252
62.39M
103.49%
+7.38M
2024Q2
228
58.25M
97.90%
+16.13M
2024Q1
182
46.83M
84.41%
+22.74M
2023Q4
113
32.29M
78.79%
+19.76M
2023Q3
82
6.26M
40.47%
+930.23K
2023Q2
81
5.83M
36.98%
+582.43K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
6.17M
7.09%
+2.28M
+58.46%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
8.28M
9.51%
+720.66K
+9.54%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.17M
5.94%
+62.24K
+1.22%
Jun 30, 2025
Redmile Group, LLC
4.87M
5.6%
-488.96K
-9.12%
Jun 30, 2025
Enavate Sciences GP, LLC
4.77M
5.48%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
4.69M
5.38%
+325.13K
+7.46%
Jun 30, 2025
The Vanguard Group, Inc.
4.51M
5.18%
+217.76K
+5.08%
Jun 30, 2025
EcoR1 Capital, LLC
4.08M
4.69%
--
--
Jun 30, 2025
Opaleye Management Inc.
3.53M
4.05%
-20.42K
-0.58%
Jun 30, 2025
PRIMECAP Management Company
3.02M
3.47%
-393.49K
-11.53%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.65%
Tema Oncology ETF
1.43%
WisdomTree BioRevolution Fund
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
ALPS Medical Breakthroughs ETF
0.48%
SPDR S&P Biotech ETF
0.18%
iShares Micro-Cap ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
iShares US Tech Breakthrough Multisector ETF
0.04%
iShares Russell 2000 Growth ETF
0.04%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.65%
Tema Oncology ETF
Proportion1.43%
WisdomTree BioRevolution Fund
Proportion1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.76%
ALPS Medical Breakthroughs ETF
Proportion0.48%
SPDR S&P Biotech ETF
Proportion0.18%
iShares Micro-Cap ETF
Proportion0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.11%
iShares US Tech Breakthrough Multisector ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
